Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2005
Headquarters: Franklin Lakes, New Jersey
BD is a medical technology company operating through three worldwide segments: BD Medical (injection, infusion, and surgery products), BD Diagnostics (specimen collection and analysis), and BD Biosciences (research and clinical tools). The company employs approximately 25,571 people globally. On August 31, 2005, BD completed the sale of its Clontech unit (BD Biosciences), which is now reported as Discontinued Operations.
Key Financial Metrics
Note: Specific consolidated revenue, net income, cash flow, and debt figures are incorporated by reference from Exhibit 13 (Annual Report to Shareholders) and are not explicitly detailed in the provided text. The following metrics are available from the filing text:
- Research & Development (R&D) Spend: $272 million for fiscal 2005 (compared to $236 million in 2004 and $224 million in 2003).
- Valuation and Qualifying Accounts (Trade Receivables):
- Allowance for doubtful accounts: $33,384,000 (end of period 2005).
- Allowance for cash discounts: $14,225,000 (end of period 2005).
- Total allowance: $47,609,000 (end of period 2005).
- Stock Repurchases (Q3 2005): Purchased 2,605,221 shares at an average price of $54.17 per share. Approximately 4,344,914 shares remained available for purchase under the 2004 program as of September 30, 2005.
- Customer Concentration: Sales to a single U.S. distributor accounted for approximately 11% of total revenues in fiscal 2005.
Material Changes and Operational Updates
- Divestiture: Completed the sale of the Clontech unit on August 31, 2005. Results are classified as Discontinued Operations.
- Capital Allocation: The Board authorized an additional 10 million share repurchase program on November 22, 2005, following the existing 2004 program.
- Facilities: As of November 30, 2005, BD owned and leased approximately 13,835,000 square feet of facilities worldwide, with significant manufacturing capacity in the U.S. and international locations including Europe, Asia Pacific, and Latin America.
- R&D Investment: R&D spending increased by approximately 15% year-over-year ($272 million vs. $236 million).
Guidance, Risks, and Contingencies
Legal Proceedings and Contingencies:
- Latex Gloves Litigation: BD is a defendant in approximately 524 product liability lawsuits regarding natural rubber latex. 463 cases have been closed with no liability; 45 settled for de minimis amounts. BD believes insurance covers a substantial portion of potential liability.
- Needlestick Litigation: Three pending class action suits regarding accidental needlesticks (Ohio, Oklahoma, South Carolina). BD is appealing class certification in Ohio and opposing it in other jurisdictions.
- Antitrust Investigations:
- Five purported class action suits alleging violations of federal antitrust laws regarding pricing.
- Subpoena from the Connecticut Attorney General regarding participation in the Healthcare Research & Development Institute (HRDI).
- Subpoena from the U.S. Attorney in Dallas regarding transactions with another company (BD states it is not a target).
- UN Oil-for-Food Programme: BD-France was listed in a UN report regarding suspected unauthorized payments. BD is cooperating with the UN Vendor Review Committee.
- Patent Litigation: Ongoing disputes with Therasense, Inc. regarding blood glucose monitoring patents. A suit with Dynovation Medical concluded in September 2005 with BD receiving a fully-paid patent license.
Forward-Looking Risks:
- Reimbursement: Changes in third-party payer policies (Medicare, Medicaid, private insurers) could impact pricing and sales.
- Competition: Potential FDA approval of inhaled insulin could impact sales of BD's insulin injection devices, though management expects this to be mitigated.
- Supply Chain: Reliance on sole-source suppliers for certain raw materials poses a risk of disruption.
- Regulatory: Increasing regulatory scrutiny in the U.S. and international markets (Europe, Japan, Asia Pacific).
Investor Verification Checklist
- Verify the specific consolidated revenue, net income, and cash flow figures in Exhibit 13 (Annual Report to Shareholders), as they are not explicitly stated in the 10-K text provided.
- Review the status of the UN Oil-for-Food Programme inquiry and any potential debarment or financial penalties.
- Monitor the outcome of the pending antitrust class action lawsuits and the Connecticut Attorney General's investigation.
- Assess the impact of the Clontech divestiture on the BD Biosciences segment's future growth trajectory.
- Confirm the extent of insurance coverage for the latex glove and needlestick litigation liabilities.
- Review the "Financial Review" section in Exhibit 13 for detailed margin analysis and segment performance.